Thus, the blockade of PD-L1 can increase the CD8+ cell infiltration into the tumor environment to promote an anti-tumor immune response (Miura et al., 2017; Stasikowska‐Kanicka et al., 2018; Massi et al., 2019). The gene discussed is CD274; the disease is neoplasm.